Europe did not have an innovation problem. It had an implementation problem.
In Brussels, a gathering of European cancer leaders confronted not the limits of science, but the limits of political will. Mark Lawler of Queen's University Belfast emerged from two days of deliberation with a sobering observation: a continent capable of mobilizing against a pandemic has yet to summon the same resolve for a disease that quietly claims lives across every border. The challenge is not discovery — it is delivery, coordination, and the courage to treat cancer as a shared European burden rather than a national inconvenience.
- Cancer is being quietly deprioritized across European health systems, with some voices even suggesting the disease is 'essentially solved' — a dangerous misconception that Lawler and others are urgently pushing back against.
- Four compounding crises — workforce shortages, entrenched inequalities in care access, bureaucratic delays in clinical trials, and shrinking health budgets — are widening the gap between what medicine can do and what patients actually receive.
- A rare current of optimism ran through the Brussels conference: health ministers are learning new funding arguments, trial acceleration pathways are being mapped, and the room broadly agreed that European nations must compete against cancer, not against each other.
- The clearest demand to emerge was a shift from innovation to implementation — Europe already has treatments and knowledge; the failure is in getting them to patients equitably and at speed.
- Patient data, largely unused despite patients assuming otherwise, and the COVID-era model of continental coordination were both named as underutilized assets that could accelerate outcomes if political will catches up with scientific readiness.
Mark Lawler arrived at The Economist World Cancer Series Europe in Brussels expecting to hear about breakthroughs. What he found instead was a more unsettling conversation — one about a continent quietly retreating from its commitment to fighting cancer. As a professor of translational cancer genomics at Queen's University Belfast, Lawler had watched health budgets lose their protected status, becoming just one claim among many in an increasingly crowded field of competing priorities. He had even heard colleagues suggest cancer was essentially fixed, a notion he found both factually wrong and genuinely alarming.
The two-day gathering kept returning to four stubborn problems: a thinning cancer workforce, stark inequalities in who could access trials and treatments, bureaucratic delays slowing clinical research, and budgets being squeezed from every direction. None of these were new, but the distance between what was medically possible and what patients were actually receiving had grown harder to ignore.
And yet the conference was not without hope. Health ministers were learning to make the economic case for cancer investment to finance ministries. Researchers had charted faster routes through clinical trial processes. Most importantly, the room had coalesced around a single animating idea: European nations should be united against cancer, not divided by it — the same spirit that had driven the continent's pandemic response.
Lawler's argument was pointed. Europe does not have an innovation problem; it has an implementation problem. Treatments exist that are not reaching patients. Data exists that is not being used — many patients believe their information is already informing research when it is not. Fixing this means involving patients from the very beginning of research design, scaling up cross-border trials, and investing seriously in prevention and early detection.
The model he pointed to was COVID: a moment when political urgency matched scientific readiness and produced coordinated, continent-wide action. A Vice President of the European Parliament had already spoken of a 'Health in All Policies' framework and a €90 billion health budget. Whether the political will exists to follow through — that, Lawler suggested, was the only question that remained.
Mark Lawler stood in Brussels at the end of two days of intensive conversation about cancer in Europe, and what struck him most was not what the room had solved, but what it had failed to protect. Lawler, who holds the chair in translational cancer genomics at Queen's University Belfast and directs postgraduate studies there, had come to The Economist World Cancer Series Europe expecting to hear about breakthroughs. Instead, he found himself confronting a more fundamental problem: Europe's health systems were treating cancer as a solved problem, or worse, as a lower priority than other diseases competing for the same shrinking pool of money.
The core issue, as Lawler saw it, was structural. Health in Europe no longer had its own protected budget. It had become one priority among many, jostling for attention and resources alongside cardiovascular disease, mental health, and whatever crisis demanded immediate attention. He had even heard colleagues suggest that cancer was essentially fixed—that the time had come to move on to other conditions. This casual dismissal alarmed him. Cancer was emphatically not fixed. The disease remained a leading cause of death across the continent, and yet the systems designed to fight it were fragmenting under budget pressure and lack of coordination.
Over the two days in Brussels, the conversation had circled around four persistent problems. The cancer workforce was stretched thin, with shortages in oncologists, nurses, and support staff across European nations. Inequalities in cancer care persisted—some patients had access to cutting-edge trials and treatments while others in neighboring countries did not. Clinical trials themselves faced delays and bureaucratic obstacles that slowed the pace of discovery. And budgets, perpetually inadequate, were being squeezed further as governments faced competing demands. These were not new problems, but they had become more urgent as the gap between what was possible and what was actually being delivered widened.
Yet the conference had also surfaced something encouraging. There were solutions on the table. Health ministers were learning new ways to pitch funding requests to their finance counterparts. Researchers had identified pathways to accelerate clinical trials. Breakthroughs in treatment and detection were emerging. And underneath it all ran a single theme that Lawler found genuinely hopeful: collaboration. The room had embraced the idea that European nations should compete against cancer, not against each other. This was the spirit that had mobilized the continent during COVID. Why not apply it to cancer?
Lawler's call was direct. Europe needed to treat cancer as a pan-European priority, the way it had treated the pandemic. The Vice President of the European Parliament had spoken of a "Health in All Policies" approach and had advocated for a €90 billion budget for health across the continent. That kind of coordinated, adequately funded effort was what cancer required. But it would only work if the focus shifted from innovation alone to implementation—from discovering new treatments to actually getting them to patients who needed them. Europe did not have an innovation problem. It had an implementation problem.
This meant listening to patients, genuinely and early. Many patients believed their data was already being used in research, when in fact it was not. Involving them from the beginning of research design, not as an afterthought, would accelerate discovery and ensure that the work being done actually mattered to the people it was meant to help. It meant not forgetting prevention and early detection, which could spare thousands from the burden of advanced disease. It meant running clinical trials and real-world studies at scale, then sharing what was learned across borders so that every nation could benefit from every discovery. And it meant delivering both a health dividend and an economic one—showing that investing in cancer control paid dividends not just in lives saved, but in productivity, reduced long-term care costs, and stronger economies.
Lawler knew this was not easy. Coordinating across European health systems meant navigating different regulations, different funding mechanisms, different political priorities. But he had seen what was possible when nations committed to a shared goal. The path forward required speed and scale, and it required the willingness to work together. If Europe could do it for COVID, it could do it for cancer. The question was whether the political will existed to match the clinical and scientific will that was already in the room.
Citas Notables
Cancer most emphatically not fixed.— Mark Lawler
Why can't we address cancer related issues at a pan European level – we did it for COVID – Why can't we do it for Cancer?— Mark Lawler
La Conversación del Hearth Otra perspectiva de la historia
Why does Lawler think Europe is treating cancer as solved when it clearly isn't?
Because health budgets are no longer protected. Cancer has to compete with every other disease for money, and some people have started saying we should move on to other priorities. It's a dangerous misconception born from real progress—we've made genuine advances—but it's being used to justify deprioritization.
What's the difference between an innovation problem and an implementation problem?
Europe has the science. Researchers are discovering new treatments and approaches. The bottleneck is getting those discoveries to actual patients. Clinical trials are delayed by bureaucracy. Data isn't being shared across borders. Patients aren't involved early enough. The solutions exist; they're just not being deployed at scale.
He mentions patients thinking their data is already being used. Why does that matter?
Because it reveals a trust gap and a coordination failure. Patients are willing to contribute their data to research—they want to help. But the systems aren't set up to use it effectively or to tell patients what's happening with it. That's a massive missed opportunity for accelerating discovery.
What does he mean by delivering both a health and economic dividend?
Cancer treatment is expensive. Prevention and early detection are cheaper. If you invest in catching cancer earlier, you reduce the burden on healthcare systems and keep people productive longer. It's not just about saving lives—it's about making the economic case to finance ministers who control the money.
Why does he keep returning to COVID as a model?
Because COVID proved Europe could coordinate at scale when it mattered. Regulations were harmonized. Resources were mobilized across borders. Information was shared rapidly. If that political will exists for a pandemic, why not for a disease that kills more people every year than COVID did at its peak?
Is he optimistic?
Cautiously. He saw real momentum in Brussels—genuine commitment from researchers, health leaders, even parliament. But he's also realistic about the structural barriers. The optimism is conditional on whether Europe actually chooses to act.